Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115088
Chunk: 3

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 3
---
 note due 18 months from the date of issuance in the principal amount of $101,875,000 (the “Oramed Note”), and (B) warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock, with an exercise price of $0.01 per share and restrictions on exercisability (as more fully described elsewhere in this prospectus) (collectively, the “Penny Warrants”), and (ii) caused certain outstanding warrants to purchase up to an aggregate of 114,286 shares of Common Stock, with an exercise price of $402.50 per whole share, that we acquired from Sorrento pursuant to the Sorrento SPA (as defined and described elsewhere in this prospectus) to be transferred to Oramed (the “Transferred Warrants”). See the section titled “Certain Relationships and Related Party Transactions” for additional information regarding the Scilex-Oramed SPA and transactions related thereto.

We are registering the resale of the Resale Shares as required by that certain Registration Rights Agreement between us and Oramed, dated September 21, 2023 (the “Oramed RRA”).

Our registration of the Resale Shares covered by this prospectus does not mean that the Selling Stockholder will offer or sell any of the Resale Shares. The Selling Stockholder may sell the Resale Shares covered by this prospectus in a number of different ways and at varying prices. For additional information on the possible methods of sale that may be used by the Selling Stockholder, you should refer to the section of this prospectus titled “Plan of Distribution” beginning on page 259 of this prospectus.

We will not receive any of the proceeds from the resale of the Resale Shares sold by the Selling Stockholder. We will, however, receive proceeds of up to $65,000 from the exercise of the remaining Penny Warrants, assuming the exercise in full of all of the Penny Warrants for cash, but not from the sale of the shares of Common Stock issuable upon such exercise.

The sale of all the Resale Shares being offered in this prospectus could result in a significant decline in the public trading price of our securities. Despite such decline in the public trading price, the Selling Stockholder may still experience a positive rate of return on the securities they acquired due to the difference in the purchase prices. Based on the closing price of our Common Stock of $5.43 on May 5, 2025, Oramed may experience